Advertisement

Picture EBD Group BIO-Europe Spring 2017 BES Barcelona Spain March 600x60px
Document › Details

Johnson & Johnson Inc.. (6/28/12). "Press Release: Janssen Acquires Corimmun". Neuss.

Organisations Organisation Janssen-Cilag GmbH
  Group Johnson & Johnson (JnJ) (Group)
  Organisation 2 Corimmun GmbH
  Group Johnson & Johnson (JnJ) (Group)
Products Product COR-1
  Product 2 cardiovascular drug
Index term Index term Corimmun–JnJ: investment, 201206 acquisition €100m + milestones durch Janssen-Cilag GmbH
     


Janssen-Cilag GmbH (Janssen) today announced it has completed the acquisition of Corimmun GmbH, a privately held drug development company in Germany, for an undisclosed upfront payment and a contingent future clinical milestone payment.

Corimmun's lead compound, COR-1, is a small cyclic peptide currently in early clinical development for the treatment of heart failure. COR-1 has been shown in preclinical studies to improve heart function by decreasing autoimmune, beta 1 receptor-simulating antibody effects. Under terms of the agreement, Janssen and its affiliates immediately assume full development and global commercialization responsibilities for the compound.

Heart failure is generally a progressive disease characterized by the heart muscle's inability to adequately pump oxygenated blood through the body. An estimated 23 million people around the globe have been diagnosed with heart failure, a number that is projected to increase. For most causes of heart failure, there is no known cure.

"The prevalence of heart failure is rising rapidly, and COR-1 is an early stage development compound with a novel mechanism for treating heart failure that has the potential to improve heart function by suppressing antibodies that can exacerbate this condition," said Peter M. DiBattiste, M.D., Global Therapeutic Area Head, Cardiovascular Disease and Metabolism at Janssen Research & Development. "This acquisition demonstrates Janssen's commitment to investing in innovative science in an area of great unmet medical need, where new therapies can improve the quality of patient care."


About Janssen

At Janssen we are dedicated to addressing and solving some of the most important unmet medical needs of our time in oncology, immunology, neuroscience, infectious diseases and vaccines, and cardiovascular and metabolic diseases. Driven by our commitment to patients, we develop innovative products, services and healthcare solutions to help people throughout the world. Janssen-Cilag GmbH and Janssen Research & Development, LLC are part of the Janssen Pharmaceutical Companies of Johnson & Johnson. Please visit http://www.janssenrnd.com for more information.


# # #

Media contacts:
Christina Chan
Phone: 908.927.5769
Mobile: 908.625.2406
cchan20@its.jnj.com

Investor contacts:
Stan Panasewicz
Phone: 732.524.2524

Louise Mehrotra
Phone: 732.524.6491

   
Record changed: 2016-05-31

Advertisement

Picture VIB Conferences Revolutionizing Next Gen Sequencing 2017 600x60px

More documents for Johnson & Johnson (JnJ) (Group)


To subscribe to our free, monthly newsletter for the life sciences in German-speaking Europe (DE, AT & CH), please send an e-mail to info@iito.de and simply fill the subject line with the word »LSG newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

Picture Sacura e.tract software 2017 600x60px wpa




» top

Advertisements

Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture AB Sciex Berliner LCMSMS Symposium 2017 Right 120x80px Picture VIB Conferences Revolutionizing Next Gen Sequencing 2017 120x180px Picture BIO Deutschland Dt Biotechnologietage DBT 2017 Hannover April 120x240px Picture EBD Group BIO-Europe Spring 2017 BES Barcelona Spain March 120x180px Picture Sacura e.tract software 2017 Barcelona 120x240px wpssy Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px Banner Fairtec GmbH Solutions for Smarter Business Events Exhibitions 120x120px Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px